Early Implantation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Patients With Liver Cirrhosis and Ascites: a Multicentre, Randomised Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 134
- 试验地点
- 2
- 主要终点
- Transplantation-free survival (TFS)
研究概览
简要总结
The aim of this clinical trial is to compare the safety and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) implantation with standard treatment (diuretic medications, and if necessary, paracenteses) in patients with liver cirrhosis and development of ascites as the first decompensating event.
By creating a shunt between the liver vein and the portal vein, blood is diverted from the portal vein directly into the hepatic vein, which results in a reduction of pressure in the portal vein so that development of ascites is reduced.
详细描述
Complications in patients with liver cirrhosis are mainly due to the development of clinical significant portal hypertension. These complications include development of varices and ascites. Implantation of a transjugular intrahepatic portosystemic shunt (TIPS) has emerged as a safe and effective interventional treatment of portal hypertension. TIPS implantation is recommended for secondary prophylaxis of variceal bleeding. Further, in patients with acute variceal bleeding, early TIPS implantation within 72 hours after the bleeding episode is associated with a lower re-bleeding rate and also improved survival in high risk patients. In patients with ascites, TIPS implantation is recommend in more advanced stages when conservative treatment has failed to control ascites. Importantly, ascites clearance can be achieved in only 51% in these patients. Recently, it has been shown that patients with a lower paracenteses frequency have a higher chance of ascites control compared to patients with long-term paracenteses. These data suggest that TIPS implantation in patients with ascites should not be delayed comparable to patients with acute variceal bleeding. The presented study aims to analyse the concept of early TIPS implantation in patients with liver cirrhosis and ascites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients eligible for inclusion in this trial must meet all of the following criteria:
- •Patients ≥ 18 years and < 80 years
- •Liver cirrhosis as documented by previous liver biopsy or by a combination of typical clinical, biochemical and sonographic features
- •Ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites
- •Ability to understand the nature of the trial and the trial related procedures and to comply with them
排除标准
- •Patients eligible for this trial must not meet any of the following criteria:
- •Treatment refractory or recurrent ascites at the time of study inclusion
- •Patients with concomitant variceal bleeding fulfilling the criteria for pre-emptive TIPS implantation (Child-Pugh class C < 14 points or Child-Pugh class B >7 with active bleeding at initial endoscopy or hepatic venous pressure gradient [HVPG] > 20 mmHg at the time of bleeding)
- •Budd-Chiari syndrome
- •Portal vein thrombosis (PVT)
- •Spontaneous bacterial peritonitis (SBP)
- •Uncontrolled systemic infection (defined as an increase of > 20% if inflammatory parameters [C-reactive protein, procalcitonin, leukocytes] and/or sepsis as a reason for development of ascites
- •Cardiac cirrhosis (defined as the development of liver cirrhosis in a patient with cardiac heart failure due to primary cardiac disease)
- •Clinical significant cardiac disease (NYHA ≥II)
- •Untreated valvular heart disease: middle to high-grade valve stenosis or insufficiency (applies to mitral, tricuspid, aortic and pulmonary valves)
- •Diastolic dysfunction grade III, stated by transthoracic echocardiogram (TTE)
- •Reduced left ventricular ejection fraction ≤50%
- •Pulmonary hypertension (mean pulmonary arterial pressure > 45 mmHg)
- •Bilirubin > 3 mg/dl
- •Obstructive cholestasis
- •Hepatorenal syndrome type AKI (HRS-AKI)
- •Acute on chronic liver failure
- •Benign liver tumor within the potential puncture tract
- •Patient after liver transplantation
- •Prior TIPS implantation
- •Ongoing and/or recurrent hepatic encephalopathy (grade >II)
- •Active tumor disease including hepatocellular carcinoma defined as need for chemotherapy, radiation therapy, interventional or surgical treatment
- •New onset of antiviral treatment for chronic hepatitis B virus (HBV) infection within the last 3 months
- •Untreated chronic hepatitis C virus (HCV) infection
- •Life expectancy <1 year
- •Pregnant or breastfeeding women
- •Patients without the legal capacity who are unable to understand the nature, significance and consequences of the study
- •Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed
- •Person who is in a relationship of dependence/employment with the sponsor or the investigator
研究组 & 干预措施
Transjugular intrahepatic portosystemic shunt (TIPS)
Patients will receive TIPS implantation if ascites as the first single decompensating event with grade 2 ascites and MELD ≥ 15 OR grade 3 ascites occurs.
干预措施: Transjugular intrahepatic portosystemic shunt (TIPS) (Procedure)
Standard medical treatment
Patients in this group will receive standard medical treatment according to the current EASL guidelines (salt restriction, diuretic treatment, carvedilol, large-volume paracentesis if necessary, albumin substitution if more than 5 litre of ascites is removed)
结局指标
主要结局
Transplantation-free survival (TFS)
时间窗: Through study completion, an average of 12 months
The primary objective of this study is to assess a survival benefit in patients with early allocation to TIPS implantation in comparison to patients with standard medical treatment (SMT).
次要结局
- Rate of TIPS implantation in the standard medical treatment group(Through study completion, an average of 12 months)
- Rate of TIPS dysfunction(Through study completion, an average of 12 months)
- Assessment of quality of life(Through study completion, an average of 1 year: at study inclusion, at 6 and 12 months after randomisation)
- Time to ascites with need for paracenteses(Through study completion, an average of 12 months)
研究者
Prof. Dr. Dominik Bettinger
Principal Investigator
University Hospital Freiburg